Stockreport

LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress [Yahoo! Finance]

Graphite Bio, Inc.  (GRPH) 
NASDAQ:AMEX Investor Relations: alabamagraphite.com/investors-page
PDF – Topline data from registration-enabling Phase 3 CLARITY trials for lead assets LNZ100 and LNZ101 expected in April 2024 – – Strong balance sheet with approximately [Read more]